Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by KalVista Pharmaceuticals, Inc.
< Previous
1
2
3
4
5
6
Next >
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
October 06, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
October 06, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
October 02, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress
September 26, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031
September 24, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes
September 24, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema
September 19, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results
September 11, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
September 04, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025
August 27, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union
August 11, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
July 25, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
July 15, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
July 10, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
July 07, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
June 26, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
June 16, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
June 13, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
June 05, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
June 02, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
May 22, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
April 30, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
April 08, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.